{"ticker": {"uuid": "2d37cf9c-7284-4110-ac6f-628f948bb92e", "symbol": "IMMP", "name": "Immutep Ltd ADR", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Immutep(IMMP) Stock Options Chain | Quotes & News", "summary": "This entry consists solely of a title and indicates a stock options chain, quotes, and news for Immutep (IMMP). No further article content was provided.", "url": "https://www.moomoo.com/stock/IMMP-US/options-chain?chain_id=Name1K9-3FXPhg.1kkbpo0&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A33,%22f%22%3A%22mm%2Fnews%2Fpost%2F25157929%22%7D", "source_name": "Moomoo", "published_at": "2026-07-21T09:11:04", "published_display": "21 Jul 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immutep highlights encouraging survival data and key clinical milestones", "summary": "Immutep (ASX: IMM; Nasdaq: IMMP) CEO Marc Voigt discussed encouraging new overall survival data from the INSIGHT-003 trial, showing patients achieved a median overall survival of over 30 months. He also provided updates on the ongoing root cause analysis for the TACTI-004 Phase I", "url": "https://www.sharecafe.com.au/2026/07/16/immutep-highlights-encouraging-survival-data-and-key-clinical-milestones/", "source_name": "Sharecafe", "published_at": "2026-07-16T01:41:01", "published_display": "16 Jul 2026 01:41", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Granted New US Patent for Cancer Treatment Methods", "summary": "Immutep, a biotechnology company, has been granted a new U.S. patent for its intellectual property covering methods of treating cancer using its IMP321 (eftilagimod alpha) product. The patent, which extends protection until January 2038, specifically covers the use of IMP321 in c", "url": "https://www.moomoo.com/news/post/72938114/immutep-granted-new-us-patent-for-cancer-treatment-methods?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-14T18:13:03", "published_display": "14 Jul 2026 18:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A new Immutep patent covers cancer treatment with eftilagimod alfa through 2036", "summary": "Immutep (NASDAQ: IMMP) has secured its fourth U.S. patent for eftilagimod alfa (efti) in combination with PD-1 pathway inhibitors, which protects methods for treating cancer and is valid until January 20, 2036. This new patent strengthens Immutep's intellectual property estate fo", "url": "https://www.stocktitan.net/news/IMMP/immutep-secures-fourth-united-states-patent-for-eftilagimod-alfa-in-3wwtzsy7mzzr.html", "source_name": "Stock Titan", "published_at": "2026-07-14T18:13:03", "published_display": "14 Jul 2026 18:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (IMMP) Secures New Patent for Cancer Treatment Innovatio", "summary": "Immutep (IMMP) has secured a new patent for its cancer treatment innovation. This development is expected to strengthen the company's intellectual property in the biotechnology sector. Further details about the specific innovation and its implications for cancer treatment are ant", "url": "https://www.gurufocus.com/news/8957507/immutep-immp-secures-new-patent-for-cancer-treatment-innovations", "source_name": "GuruFocus", "published_at": "2026-07-14T14:18:25", "published_display": "14 Jul 2026 14:18", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor", "summary": "Immutep Limited has announced the grant of its fourth United States patent for eftilagimod alfa in combination with PD-1 pathway inhibitors for cancer treatment. This patent, expiring in 2036, expands the company's intellectual property and supports future development and busines", "url": "https://finance.yahoo.com/healthcare/articles/immutep-secures-fourth-united-states-120000690.html", "source_name": "Market source", "published_at": "2026-07-14T11:39:38", "published_display": "14 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens maintains Immutep stock rating on cash analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNbFNVd3BkakNkUlY3bHdPWUpFQ0kzang2bGdHRU04T3VqZW1KVTFtNXpqS25zQTd4dnp1em1tNDlmN2Yya3F0UlVGdXprS281dDJwNGgzdmJLOVMxMVRJODRNYVNYMXplcEhFSnFxTS1pWHJUZk50dkR6Qy1ZdW4zcXZBZ3JfOVhBOHhqRFNMOFdBLVpnT2R3eDY1dVFXZ08zN0MzRDJOVllDSkEzVDVOeUlGM3VNT3M?oc=5", "source_name": "Investing.com", "published_at": "2026-07-14T09:52:02+00:00", "published_display": "14 Jul 2026 09:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] IMMUTEP Ltd Current Report (Foreign Issuer) | IMMP SEC Filing - Form 6-K", "summary": "Immutep Limited reported mature results from its INSIGHT-003 Phase I trial, showing a median Overall Survival of 30.9 months for eftilagimod alfa (efti) in first-line advanced non-squamous NSCLC, which compares favorably to historical benchmarks despite a high proportion of patie", "url": "https://www.stocktitan.net/sec-filings/IMMP/6-k-immutep-ltd-current-report-foreign-issuer-992d57e94ed7.html", "source_name": "Stock Titan", "published_at": "2026-07-14T09:39:38", "published_display": "14 Jul 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (NASDAQ: IMMP) posts 30.9-month survival, reviews TACTI-004 trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQaWJPVTFhZGhEcmtCc196Y2wtMGNoeUxQekxHVl9vTHl1NUtISEljS2o5enA4aWlPOGJha3ctVzJiTlNxTzRJQTk1T0c0QW5sM3dxWjhBMkFWVWl6b0JDSnZKQ3VVSFl5cTk0YkxHMzU2YkJmNmNGQWF6a094bG1WelNlX3NOT2cwV2d5Ym15X2JhNW8yYWF0N1V5VFI3TlNPVHpyZGhFdkpyWlk?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T07:00:00+00:00", "published_display": "14 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep secures USPTO patent for cancer treatment anew", "summary": "Immutep (ASX:IMM) has secured a fourth patent from the United States Patent and Trademark Office for its combination cancer immunotherapy treatments, protecting future clinical development and business opportunities. The patent is set to expire in 2036. Following the announcement", "url": "https://grafa.com/en/news/australia/immutep-secures-uspto-patent-for-cancer-treatment-anew", "source_name": "grafa.com", "published_at": "2026-07-14T06:00:04", "published_display": "14 Jul 2026 06:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep cancer candidate shows strong median survival in lung cancer as company considers conflicting trial results", "summary": "Immutep (ASX:IMU) has released mature overall survival data from its INSIGHT\u2011003 trial for eftilagimod alfa (efti) in first-line non\u2011squamous non\u2011small cell lung cancer, showing a median overall survival of 30.9 months. These positive results, particularly in patients with low PD", "url": "https://biotechdispatch.com.au/news/immutep-cancer-candidate-shows-strong-median-survival-in-lung-cancer-as-company-consider-conflic", "source_name": "BiotechDispatch", "published_at": "2026-07-14T00:12:04", "published_display": "14 Jul 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/immutep-provides-clinical-1st-line-120000177.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T12:00:00+00:00", "published_display": "13 Jul 2026 12:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Says Median Overall Survival 30.9 Months for Non-Small Cell Lung Cancer Patients in Phase One Trial", "summary": "Immutep announced that its efti plus pembrolizumab combination therapy showed a median overall survival of 30.9 months in a Phase I trial for previously treated non-small cell lung cancer patients. This data, presented at the ESMO Immuno-Oncology Asia Congress 2023, is mature and", "url": "https://www.moomoo.com/news/post/72835534/immutep-says-median-overall-survival-30-9-months-for-non?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T08:12:04", "published_display": "13 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Health Check: Immutep shares bounce on revived lung cancer treatment hopes", "summary": "Immutep (ASX:IMM) shares surged 30% after releasing positive overall survival data from its INSIGHT-003 lung cancer study, offering renewed hope for its eftilagimod alfa treatment. This comes after the previous TACTI-004 trial was discontinued due to a futility analysis. The comp", "url": "https://stockhead.com.au/health/health-check-immutep-shares-bounce-on-revived-lung-cancer-treatment-hopes/", "source_name": "Stockhead", "published_at": "2026-07-13T02:41:23", "published_display": "13 Jul 2026 02:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (ASX:IMM) Reports Mature Survival Data From INSIGHT-003 Trial", "summary": "Immutep (ASX:IMM) has released mature overall survival data from its INSIGHT-003 trial for first-line non-small cell lung cancer, showing a median overall survival of 30.9 months, which compares favorably to a 22.0-month median overall survival in a similar registrational trial. ", "url": "https://kalkine.com.au/news/healthcare/immutep-asximm-reports-mature-survival-data-from-insight-003-trial", "source_name": "Kalkine", "published_at": "2026-07-13T01:41:23", "published_display": "13 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm", "summary": "The Schall Law Firm is reminding investors of a class action lawsuit against Immutep Limited (NASDAQ: IMMP) for alleged securities fraud. The lawsuit claims Immutep made false and misleading statements about its TACTI-004 trial, which the company allegedly knew would fail its pri", "url": "https://www.barchart.com/story/news/3147131/immp-investors-have-opportunity-to-lead-immutep-limited-securities-fraud-lawsuit-with-the-schall-law-firm", "source_name": "Barchart", "published_at": "2026-07-07T17:10:38", "published_display": "07 Jul 2026 17:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMP Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "Immutep Ltd (IMMP) generates its revenue primarily from Cancer Immunotherapy, which accounts for 51.4% of its sales. The company exhibits a strong gross margin of 100.00% but shows negative operating and net margins, indicating challenges in translating revenue into profit. IMMP,", "url": "https://intellectia.ai/en/stock/IMMP/financials", "source_name": "Intellectia AI", "published_at": "2026-07-06T10:41:24", "published_display": "06 Jul 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SueWallSt Reminds Immutep Limited Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 6, 2026 - IMMP", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxNTzJWcHMtWVdfd2pFa0ZPQVMyZ2tHS1lDT21nNmZKMk9VN08ybTBkZF9IbVg1dERxZV9qUEJfZWs4TVBmZ2NPTUZxcmtSX2Z5M3NNYmVsYWNBeUNwX0dTR3BkemlGVjFUWkYtcm85QnhvamIxMl9MOEV1Ti1TRFFpMzUtTDI1WjBueUc3WnRfdVRvelVuOVNtVkN6NHdoZmgwSFBrRmRYTUpaSUdwY0Qzdm82UDB0U1JsNE4xOGhuYldJdzJlYjBWNzVSUGNtMmtncGNMeDJaaTdNcXdEVHI4emF6RHZFSFpFUkItQmVLN1JWMHNFcWhjNWN4N0xwcGxHSURfZUFUeDN5SWFMbXdrTDJObWFMQ3c?oc=5", "source_name": "PR Newswire", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Graphic Packaging Holding Company (GPK), Immutep Limited (IMMP), and Phreesia, Inc. (PHR) Announced by Holzer & Holzer, LLC", "summary": "Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Graphic Packaging Holding Company (GPK), Immutep Limited (IMMP), and Phreesia, Inc. (PHR). The lawsuits allege materially false and/or misleading statements regarding inventory m", "url": "https://www.globenewswire.com/news-release/2026/07/01/3320494/0/en/lead-plaintiff-deadlines-in-shareholder-class-action-lawsuits-against-graphic-packaging-holding-company-gpk-immutep-limited-immp-and-phreesia-inc-phr-announced-by-holzer-holzer-llc.html", "source_name": "GlobeNewswire", "published_at": "2026-07-01T10:40:49", "published_display": "01 Jul 2026 10:40", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Immutep Ltd \u2013 LS:A2H81H", "summary": "The article provides financial information for Immutep Ltd (A2H81H) on Lang & Schwarz Tradecenter via TradingView. It specifically focuses on the \"Price to book forward\" metric. The page offers an overview of financials, news, and technical analysis, set within the broader Tradin", "url": "https://www.tradingview.com/symbols/LS-A2H81H/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T07:40:49", "published_display": "01 Jul 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Immutep Ltd \u2013 MUN:YP1B", "summary": "The article displays the enterprise value to EBITDA forward for Immutep Ltd (MUN:YP1B) on the Munich Stock Exchange. It indicates that the market is closed with no trades. The core content is a financial metric displayed within the TradingView platform.", "url": "https://www.tradingview.com/symbols/MUN-YP1B/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T06:40:49", "published_display": "01 Jul 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6,", "summary": "Bernstein Liebhard LLP reminds investors of Immutep Limited (NASDAQ: IMMP) who suffered losses that they have until July 6, 2026, to join a securities fraud class action lawsuit. The lawsuit alleges that Immutep made false and misleading statements, leading to artificially inflat", "url": "https://www.globenewswire.com/news-release/2026/07/01/3320706/0/en/immutep-limited-investors-with-losses-have-until-july-6-2026-to-join-securities-class-action-bernstein-liebhard-llp-announces-deadline.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T18:10:09", "published_display": "29 Jun 2026 18:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "YP1A Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a price target and analyst ratings for Immutep Ltd Sponsored ADR (YP1A) for 2027. One analyst offers a 1-year price forecast of 1.32. Based on two analysts, no specific estimates for EPS or revenue are detailed in the provided content.", "url": "https://www.tradingview.com/symbols/GETTEX-YP1A/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-29T13:14:16", "published_display": "29 Jun 2026 13:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Immutep Ltd \u2013 ASX:IMM", "summary": "This page provides financial data for Immutep Ltd (ASX:IMM), specifically focusing on its forward Price to Earnings (P/E) ratio. It indicates that the market was closed with no trades at the time of viewing, suggesting the data presented is for informational purposes.", "url": "https://www.tradingview.com/symbols/ASX-IMM/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:39:24", "published_display": "28 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A2H8YL Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a price target and analyst ratings for Immutep Ltd Sponsored ADR (A2H8YL). One analyst offers a 1-year price forecast, with a target of 1.32. The ratings are based on two analysts over the past three months.", "url": "https://www.tradingview.com/symbols/LS-A2H8YL/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T13:10:53", "published_display": "27 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Ltd Actuals & Estimates (ASX:IMM)", "summary": "This article provides an overview of Immutep Ltd (ASX: IMM) stock performance, analyst estimates, and financial data. It covers current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports, noting that analysts have a maximum an", "url": "https://www.tradingview.com/symbols/ASX-IMM/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T13:39:03", "published_display": "26 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Ltd Actuals & Estimates (FWB:YP1B)", "summary": "This article provides financial actuals and estimates for Immutep Ltd (FWB: YP1B), an Australian biotechnology company. It details analyst forecasts, historical stock prices, recent earnings and revenue, and confirms that the company does not pay dividends. The report also highli", "url": "https://www.tradingview.com/symbols/FWB-YP1B/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:39:24", "published_display": "26 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Immutep Ltd \u2013 FWB:YP1B", "summary": "This page displays the \"Price to sales forward\" metric for Immutep Ltd (FWB:YP1B) on the Frankfurt Stock Exchange. The specific value, change, and percentage change for this metric are presented, though the actual numerical data is not visible in the provided content. The page al", "url": "https://www.tradingview.com/symbols/FWB-YP1B/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:39:03", "published_display": "26 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Immutep Ltd \u2013 FWB:YP1B", "summary": "The article discusses the enterprise value to EBITDA forward for Immutep Ltd (FWB:YP1B) on the Frankfurt Stock Exchange. It provides financial context for the company's valuation metrics.", "url": "https://www.tradingview.com/symbols/FWB-YP1B/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T05:10:34", "published_display": "26 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Shares Rise After Maxim Group Upgrade", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immutep-shares-rise-maxim-group-185629406.html", "source_name": "MT Newswires", "published_at": "2026-06-17T18:56:29+00:00", "published_display": "17 Jun 2026 18:56", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immutep-present-positive-interim-phase-120000283.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T12:00:00+00:00", "published_display": "04 Jun 2026 12:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors Should Contact SueWallSt", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxQWnVnWTNIQkxrX2UtMkpPbGFSVHh5X2JOMUpaS3FSd2hYM2ZwV2taVWZMTmJicDlLd2RsSExRQ3hGTXBYeFgwQmFTYXBXaFg4Y0VjaWhyZHNZTE4zSFNqUmM1ZVR0dHJNSFZYalNmdmU1OWFES2FpanA2YUZfeUNRcXNvRHVRZ0VqSldnay05a2hZR2J6elNMSk9PeGFYWkRtQVlQMXExLURobDhXZmt4a2FMb2hiaFlSMFNvdFVsTnZFaG5uMEMxSWdJdUQzT3B5VWd3aF81VW9iUmNlV2VCV2N1dVFPVk9kRG55dW9qUkNuZnIwcmc?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immune response to Immutep drug linked to 7.7-month survival gain", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxORk10RVRxdVlzb2pVZF9udzVzZG9nRkp6bXpLTHA2c3FlQlljMUIxTGNhYUtVeFUzRlUxXzhxWXB3SVVUTEVUNlM5aW5xZUQyenFlRkFwbERLcXp0SV9MaE1SWjJHVUJqTkhqMnF6ZkJEaFhxcE9UeDdvME9Xbnllc1lNdFVhbTI2UDZUUHhVbnhxdTNNQUhLZEdpNXhrZEliaTVXUEZ5Wm1MSmNCeGpLU3N1RWo0RmtEY2tj?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgJBVV95cUxOVzBOSDFQUlN0dmVJNXlROW1sSmZUZHBka0stVDIzeVlKa0htdjQ0aUxyaWdDclBuZkc1NDYtVkhsYmhmSHliaDdob1p6QlpaeGtjRWdaWkhlMTQzamZVRDFvZ1RPYm9KWlNaT19Cc2lVQmxTOE5VNTU3UVl6bWZ1RlFlX0ozX2RBd0IzZmU3ZFJMYVJ2cEloT2ZERU0tRXQ2VEtCMk9VRmxpeGs3aXVtMF9sZjhqQVZvalFPUHd0TXFiOHlTWXFmakQ1cmlFSTlGR25hM2F5NG9JaUd4MUFNZG5SX3ZkZjdIdTRYWE5FVDRSTlJyd2toQklndWdJWkQzczJ1S3NKLUNBRmZ1YnE5cUhn?oc=5", "source_name": "Morningstar", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Immutep (ASX:IMM) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immutep-asx-imm-good-position-220305870.html", "source_name": "Simply Wall St.", "published_at": "2026-05-10T22:03:05+00:00", "published_display": "10 May 2026 22:03", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMUTEP LIMITED (IMMP) INVESTOR ALERT Investors With Large", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAJBVV95cUxQT3c2ZGEwUWtSVUhQU1U5LUp4aEFDUnRPTklMUElYZE53dFBacjdZY0lOci1NZFpQSmtDVDI3WVQxcy1PaS1pbU5mb0xzZGE3ZUFPN3BvTW1kNUNwQTJyRElsaDJTUjQwV1VRWWNnZmlLMkU4MG14dlJHdDd2NGVBVm5aRjhaRkRNZ3pUQlB5SXRzcEtSZXRrUzk1ekNxVHhxeTJ1ejhJQUh1VHFWalA1VTNRTW12b2N0Tm53c3Bxc1ZVNWVLTzNKUjFMeDJUcVUydHEwSFZzbzNGdkl1b3ZSRmowUEJlWTlkTHhmTWNlbFhQQTdvMTRNQkx5dFhuUEVob1Z5YXUtTDlsNUJ0enNHZlVkcHVUdnpaYVpXazlVTm1teDdodUNKODBoUTdGUjhpMU5IWWZ4SmhoN0ct?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Receives Nasdaq Notice of Bid Price Deficiency", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immutep-receives-nasdaq-notice-bid-120000160.html", "source_name": "GlobeNewswire", "published_at": "2026-04-30T12:00:00+00:00", "published_display": "30 Apr 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cancer meeting picks Immutep poster linking immune activation to survival", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQS1gtWkViWWt5TjhhSjJPdkZ2c3pleWtMVDlyNmE4ejBoTHNFczFnYWJfX3FKaF9YdFpxejhCYzRYZGI1eDFjVjZWbmVfWDk5NzhMYk83QUF2X0trNVJpTGprZ055RER5OGFIc1hRU3ZUQ1dpR1BkY20zaUpZREhSOXJCa0RsXzZYMHYtVW51bV9XV0ptc1dFYi16c0VyVk1XYV9aUlcxclppaV9IMV9HUVhraVBpQ2ttNWhmejB6U0M?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immutep shares more than double after FDA grants orphan drug designation for sarcoma candidate", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOaW80OXY0XzIzVmwxd2VabzJpNEtmX01mdmplR1N2Z0JnRXJaY0VZZHhBbjc4TzdxZ0ZGdl9hUjdfTndMSDRYQU4waV9YRjY1QV9qMnlqWURhNmQ2WTMyYTV4UlN4bXdkdzJHa2l6YlBQYTF3Y3NVTTVBNXZkMEV4WnByRHh6QXRQdXdrTWdCdnhnaXpSMEVKSWREWURyQTZ3VjZ0WGpmMEs1aC1pOE1rTVotY2dEUllkM2JMUTZPSmNWMXQyVUE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immutep Limited (IMMP) Stock Analysis: Uncovering A Potential 171.74% Upside In Biotech", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPYWNNWTRlTGRuQkFJdXBXUkFESldSQlZqaHBRTVlfOWNkb2dkUHZhampLcTlHMnZlZFhHUmduNXlqRU5la1hSZnpoM1lURENiSEpYeVBSU2RfY2duWldJbzI5RklTcW9kc212QUkyZ24zc0xKWWZSTDQ0cEdQN0ZVX1MyelJjZ3U1QWVpV3NKS0pwQk05NUE5X0pSUEl1ejBMdGVBcm1PSjEtQnB1aXc5d1p4N1cwaDNZZ2VQZ3Q1ZDZ0bHBBV2dUTERCdlZTaEk?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Limited (IMMP) Stock Analysis: Navigating a Potential 140% Upside in the Biotech Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxPT1VqNlRoZVA2bl9rb09vYlZ2TGlhVFRKdHRNY1dpOHV5Y2hGWWphY2hsUnNON2plejhGWTJGeU1yaGdmTmdGWFhyTkp5WVgyTnpFaXJFZVdYVXh4d2wtQWxqLWd0LVVBVGdMNmF5OWo5NkU4LVVOamVKSXVtaFRCM3QycVJISGxHSjNZZXcwNTJfWm1XYzRtYTlrNmotakQxRUVpak41S3huV0RKV19UTE5Zb2VqVTJqNHNxdDQxMmxXM29hemRhRTJ6WVZ1aHNpWTBOa0dNMkhCQQ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep stock plunges 80% after lung cancer trial halted", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPaFdudFFUbFJveXZEaVlGcXY5T1JNdjlNbFJnUzBaN2FfeElsRlJ5QnljbWFEMHFvNzlLZUtKY0d4c2ZLd1hjQnlWMzR3TmREQkhqMWpQQWdrSTdzSlAwdGxPWUVoMWJ6Vnd2NnlubVNJa2c1T1hmUkF6aXNLcHljbXpsSjFPT1lVWEcxaktoM0t5YzNrUFFGTUJkc2dEOTEyQUd5M21lTEFZTmhRN3l2NU1IU1Y0OHgy?oc=5", "source_name": "Investing.com", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens downgrades Immutep stock rating on lead program halt", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPdXZoZlRvUmpkcFRkdHFlcVc4em4wQ0ZZeHI5Z3FibzRVLVVlYkdXNE1JVjZlMTc3RkMwS2M5bUJxdWxibXB1WjFNY0tUWG9tMExueS1xLXhERXo5cV9FeVB0bjMyQUJIRnAwaE5SWmM3Z2IzX0ROZ3FBazBRTnpMTWUzUkJxdGVqZjhvTHZqT3lxZk9MMURsekdGRUpLUXZiaEZFUzJsR0hnU1ZLS3dDWUpDQmNYempkRDZVMkNn?oc=5", "source_name": "Investing.com", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Stock Sinks To 52-Week Low - Here's Why - Immutep (NASDAQ:IMMP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPLTE3SHhlVU1vVnBJeHBNczZBZkhoVEwtdHpRNzRrMDh2QlpjUnROOExwZ25jeUVvLVdETHl5RjV6TWZrMXBjMlMzaXlmTGZCSTQ2WVp4OTlna0pTeDctMnBKdmZ1bnJoaWdfREluUXlTSVh1eGRwUm5yT0JkM09lUVVxUzZXUDZ1MkJwalhVVGU5SFhUNkhMLVRhUHR3QXNGNXNMRkNqaDRtTUpIME14QXRHeWlsRklTV2VlMFJxMFpjWlBSX0tXYmFFRjA0Zw?oc=5", "source_name": "Benzinga", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Limited (IMMP) Stock Analysis: Exploring a Promising 247.99% Upside in Biotechnology", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxOS1ZVUmkyRTJXZk1zZ0ppMzB5RDlZUlVDRnJoek5RMmlsR3hLbXlOeWxsMEVfb2htTkNaUE9vN1VtLW9PYlM1Sm80ZDhtRjhTd1g1YUJMNzU2Snh5SlBVZEEzdHF5YUZvaU5jX0oxT1MzVVVUdk5oTUJEeWRXWkkyVGZfd0hVb0JmVkpmRFlzamx0QkJxTzBta08wcHdQNjRneTFXNFBhMkNiR29VT3VqTC1kTlBhNi1uTXhUeEdubDE3X3dfbGNPVmFvcWVna2wtVkhFeWJn?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Limited (IMMP) Stock Analysis: A 240% Potential Upside In Immunotherapy Breakthrough", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPSGlQV0xtZ3owcTNLUFlMTWEyeFdrWjVkWU9JUWt2bGpJNUdXckJTeFZhZjdmMGF2OUFNOUF3TUF3YUp2ZUJ1Z19fNXU3WEVvMGNNTUlrOE91X2JUX0JWNmtXcklPS3pNSUNJdUhkSExQWklvVnBxMVh1R2JEMGFQSGdlWG9hX05LbFVxMHZmUFR6R3FfOFh3ZDRxWkZqMTNNOXNocmxQQ1dGODBDSG5OR0tsZVhYZHdZYm9qMXFOWFJGRFhMUV9ET3RSU056SHFBUG92cG9n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Limited (IMMP) Stock Analysis: Exploring a Potential 208% Upside in Biotechnology", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxNVnlKTkt5RjUtejFuYV9hblJONmNnd3NzN245alU1bjRoLU04Nl9nWk9NM09TUENVTF9IQVRrUzNmdEF3aG1uWUVDV3F6eXluNERQQ1JvdXlzVHdfOV84M29TdE1jLXFVUHJQYVFIOUxaa2RDaW5zRzVXRElhNVdsejdsdnJDVzRlNWY1ZTk5cl9icFRRQnZmMFpsVEI2d2E3R0thOEQwT1lNdzU5aVk4TEdfWlhFQ2dNVHd4d1BSOEpVTnRvOGtya0dZN3E4c1NQdUE?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2025-12-25T08:00:00+00:00", "published_display": "25 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Immutep(IMMP) Stock Options Chain | Quotes & News", "summary": "This entry consists solely of a title and indicates a stock options chain, quotes, and news for Immutep (IMMP). No further article content was provided.", "url": "https://www.moomoo.com/stock/IMMP-US/options-chain?chain_id=Name1K9-3FXPhg.1kkbpo0&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A33,%22f%22%3A%22mm%2Fnews%2Fpost%2F25157929%22%7D", "source_name": "Moomoo", "published_at": "2026-07-21T09:11:04", "published_display": "21 Jul 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep highlights encouraging survival data and key clinical milestones", "summary": "Immutep (ASX: IMM; Nasdaq: IMMP) CEO Marc Voigt discussed encouraging new overall survival data from the INSIGHT-003 trial, showing patients achieved a median overall survival of over 30 months. He also provided updates on the ongoing root cause analysis for the TACTI-004 Phase I", "url": "https://www.sharecafe.com.au/2026/07/16/immutep-highlights-encouraging-survival-data-and-key-clinical-milestones/", "source_name": "Sharecafe", "published_at": "2026-07-16T01:41:01", "published_display": "16 Jul 2026 01:41", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Granted New US Patent for Cancer Treatment Methods", "summary": "Immutep, a biotechnology company, has been granted a new U.S. patent for its intellectual property covering methods of treating cancer using its IMP321 (eftilagimod alpha) product. The patent, which extends protection until January 2038, specifically covers the use of IMP321 in c", "url": "https://www.moomoo.com/news/post/72938114/immutep-granted-new-us-patent-for-cancer-treatment-methods?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-14T18:13:03", "published_display": "14 Jul 2026 18:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A new Immutep patent covers cancer treatment with eftilagimod alfa through 2036", "summary": "Immutep (NASDAQ: IMMP) has secured its fourth U.S. patent for eftilagimod alfa (efti) in combination with PD-1 pathway inhibitors, which protects methods for treating cancer and is valid until January 20, 2036. This new patent strengthens Immutep's intellectual property estate fo", "url": "https://www.stocktitan.net/news/IMMP/immutep-secures-fourth-united-states-patent-for-eftilagimod-alfa-in-3wwtzsy7mzzr.html", "source_name": "Stock Titan", "published_at": "2026-07-14T18:13:03", "published_display": "14 Jul 2026 18:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (IMMP) Secures New Patent for Cancer Treatment Innovatio", "summary": "Immutep (IMMP) has secured a new patent for its cancer treatment innovation. This development is expected to strengthen the company's intellectual property in the biotechnology sector. Further details about the specific innovation and its implications for cancer treatment are ant", "url": "https://www.gurufocus.com/news/8957507/immutep-immp-secures-new-patent-for-cancer-treatment-innovations", "source_name": "GuruFocus", "published_at": "2026-07-14T14:18:25", "published_display": "14 Jul 2026 14:18", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor", "summary": "Immutep Limited has announced the grant of its fourth United States patent for eftilagimod alfa in combination with PD-1 pathway inhibitors for cancer treatment. This patent, expiring in 2036, expands the company's intellectual property and supports future development and busines", "url": "https://finance.yahoo.com/healthcare/articles/immutep-secures-fourth-united-states-120000690.html", "source_name": "Market source", "published_at": "2026-07-14T11:39:38", "published_display": "14 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens maintains Immutep stock rating on cash analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNbFNVd3BkakNkUlY3bHdPWUpFQ0kzang2bGdHRU04T3VqZW1KVTFtNXpqS25zQTd4dnp1em1tNDlmN2Yya3F0UlVGdXprS281dDJwNGgzdmJLOVMxMVRJODRNYVNYMXplcEhFSnFxTS1pWHJUZk50dkR6Qy1ZdW4zcXZBZ3JfOVhBOHhqRFNMOFdBLVpnT2R3eDY1dVFXZ08zN0MzRDJOVllDSkEzVDVOeUlGM3VNT3M?oc=5", "source_name": "Investing.com", "published_at": "2026-07-14T09:52:02+00:00", "published_display": "14 Jul 2026 09:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] IMMUTEP Ltd Current Report (Foreign Issuer) | IMMP SEC Filing - Form 6-K", "summary": "Immutep Limited reported mature results from its INSIGHT-003 Phase I trial, showing a median Overall Survival of 30.9 months for eftilagimod alfa (efti) in first-line advanced non-squamous NSCLC, which compares favorably to historical benchmarks despite a high proportion of patie", "url": "https://www.stocktitan.net/sec-filings/IMMP/6-k-immutep-ltd-current-report-foreign-issuer-992d57e94ed7.html", "source_name": "Stock Titan", "published_at": "2026-07-14T09:39:38", "published_display": "14 Jul 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (NASDAQ: IMMP) posts 30.9-month survival, reviews TACTI-004 trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQaWJPVTFhZGhEcmtCc196Y2wtMGNoeUxQekxHVl9vTHl1NUtISEljS2o5enA4aWlPOGJha3ctVzJiTlNxTzRJQTk1T0c0QW5sM3dxWjhBMkFWVWl6b0JDSnZKQ3VVSFl5cTk0YkxHMzU2YkJmNmNGQWF6a094bG1WelNlX3NOT2cwV2d5Ym15X2JhNW8yYWF0N1V5VFI3TlNPVHpyZGhFdkpyWlk?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T07:00:00+00:00", "published_display": "14 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep secures USPTO patent for cancer treatment anew", "summary": "Immutep (ASX:IMM) has secured a fourth patent from the United States Patent and Trademark Office for its combination cancer immunotherapy treatments, protecting future clinical development and business opportunities. The patent is set to expire in 2036. Following the announcement", "url": "https://grafa.com/en/news/australia/immutep-secures-uspto-patent-for-cancer-treatment-anew", "source_name": "grafa.com", "published_at": "2026-07-14T06:00:04", "published_display": "14 Jul 2026 06:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep cancer candidate shows strong median survival in lung cancer as company considers conflicting trial results", "summary": "Immutep (ASX:IMU) has released mature overall survival data from its INSIGHT\u2011003 trial for eftilagimod alfa (efti) in first-line non\u2011squamous non\u2011small cell lung cancer, showing a median overall survival of 30.9 months. These positive results, particularly in patients with low PD", "url": "https://biotechdispatch.com.au/news/immutep-cancer-candidate-shows-strong-median-survival-in-lung-cancer-as-company-consider-conflic", "source_name": "BiotechDispatch", "published_at": "2026-07-14T00:12:04", "published_display": "14 Jul 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/immutep-provides-clinical-1st-line-120000177.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T12:00:00+00:00", "published_display": "13 Jul 2026 12:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Says Median Overall Survival 30.9 Months for Non-Small Cell Lung Cancer Patients in Phase One Trial", "summary": "Immutep announced that its efti plus pembrolizumab combination therapy showed a median overall survival of 30.9 months in a Phase I trial for previously treated non-small cell lung cancer patients. This data, presented at the ESMO Immuno-Oncology Asia Congress 2023, is mature and", "url": "https://www.moomoo.com/news/post/72835534/immutep-says-median-overall-survival-30-9-months-for-non?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T08:12:04", "published_display": "13 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Health Check: Immutep shares bounce on revived lung cancer treatment hopes", "summary": "Immutep (ASX:IMM) shares surged 30% after releasing positive overall survival data from its INSIGHT-003 lung cancer study, offering renewed hope for its eftilagimod alfa treatment. This comes after the previous TACTI-004 trial was discontinued due to a futility analysis. The comp", "url": "https://stockhead.com.au/health/health-check-immutep-shares-bounce-on-revived-lung-cancer-treatment-hopes/", "source_name": "Stockhead", "published_at": "2026-07-13T02:41:23", "published_display": "13 Jul 2026 02:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep (ASX:IMM) Reports Mature Survival Data From INSIGHT-003 Trial", "summary": "Immutep (ASX:IMM) has released mature overall survival data from its INSIGHT-003 trial for first-line non-small cell lung cancer, showing a median overall survival of 30.9 months, which compares favorably to a 22.0-month median overall survival in a similar registrational trial. ", "url": "https://kalkine.com.au/news/healthcare/immutep-asximm-reports-mature-survival-data-from-insight-003-trial", "source_name": "Kalkine", "published_at": "2026-07-13T01:41:23", "published_display": "13 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm", "summary": "The Schall Law Firm is reminding investors of a class action lawsuit against Immutep Limited (NASDAQ: IMMP) for alleged securities fraud. The lawsuit claims Immutep made false and misleading statements about its TACTI-004 trial, which the company allegedly knew would fail its pri", "url": "https://www.barchart.com/story/news/3147131/immp-investors-have-opportunity-to-lead-immutep-limited-securities-fraud-lawsuit-with-the-schall-law-firm", "source_name": "Barchart", "published_at": "2026-07-07T17:10:38", "published_display": "07 Jul 2026 17:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMP Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "Immutep Ltd (IMMP) generates its revenue primarily from Cancer Immunotherapy, which accounts for 51.4% of its sales. The company exhibits a strong gross margin of 100.00% but shows negative operating and net margins, indicating challenges in translating revenue into profit. IMMP,", "url": "https://intellectia.ai/en/stock/IMMP/financials", "source_name": "Intellectia AI", "published_at": "2026-07-06T10:41:24", "published_display": "06 Jul 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SueWallSt Reminds Immutep Limited Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 6, 2026 - IMMP", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxNTzJWcHMtWVdfd2pFa0ZPQVMyZ2tHS1lDT21nNmZKMk9VN08ybTBkZF9IbVg1dERxZV9qUEJfZWs4TVBmZ2NPTUZxcmtSX2Z5M3NNYmVsYWNBeUNwX0dTR3BkemlGVjFUWkYtcm85QnhvamIxMl9MOEV1Ti1TRFFpMzUtTDI1WjBueUc3WnRfdVRvelVuOVNtVkN6NHdoZmgwSFBrRmRYTUpaSUdwY0Qzdm82UDB0U1JsNE4xOGhuYldJdzJlYjBWNzVSUGNtMmtncGNMeDJaaTdNcXdEVHI4emF6RHZFSFpFUkItQmVLN1JWMHNFcWhjNWN4N0xwcGxHSURfZUFUeDN5SWFMbXdrTDJObWFMQ3c?oc=5", "source_name": "PR Newswire", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Graphic Packaging Holding Company (GPK), Immutep Limited (IMMP), and Phreesia, Inc. (PHR) Announced by Holzer & Holzer, LLC", "summary": "Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Graphic Packaging Holding Company (GPK), Immutep Limited (IMMP), and Phreesia, Inc. (PHR). The lawsuits allege materially false and/or misleading statements regarding inventory m", "url": "https://www.globenewswire.com/news-release/2026/07/01/3320494/0/en/lead-plaintiff-deadlines-in-shareholder-class-action-lawsuits-against-graphic-packaging-holding-company-gpk-immutep-limited-immp-and-phreesia-inc-phr-announced-by-holzer-holzer-llc.html", "source_name": "GlobeNewswire", "published_at": "2026-07-01T10:40:49", "published_display": "01 Jul 2026 10:40", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Immutep Ltd \u2013 LS:A2H81H", "summary": "The article provides financial information for Immutep Ltd (A2H81H) on Lang & Schwarz Tradecenter via TradingView. It specifically focuses on the \"Price to book forward\" metric. The page offers an overview of financials, news, and technical analysis, set within the broader Tradin", "url": "https://www.tradingview.com/symbols/LS-A2H81H/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T07:40:49", "published_display": "01 Jul 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Immutep Ltd \u2013 MUN:YP1B", "summary": "The article displays the enterprise value to EBITDA forward for Immutep Ltd (MUN:YP1B) on the Munich Stock Exchange. It indicates that the market is closed with no trades. The core content is a financial metric displayed within the TradingView platform.", "url": "https://www.tradingview.com/symbols/MUN-YP1B/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T06:40:49", "published_display": "01 Jul 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6,", "summary": "Bernstein Liebhard LLP reminds investors of Immutep Limited (NASDAQ: IMMP) who suffered losses that they have until July 6, 2026, to join a securities fraud class action lawsuit. The lawsuit alleges that Immutep made false and misleading statements, leading to artificially inflat", "url": "https://www.globenewswire.com/news-release/2026/07/01/3320706/0/en/immutep-limited-investors-with-losses-have-until-july-6-2026-to-join-securities-class-action-bernstein-liebhard-llp-announces-deadline.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T18:10:09", "published_display": "29 Jun 2026 18:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "YP1A Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a price target and analyst ratings for Immutep Ltd Sponsored ADR (YP1A) for 2027. One analyst offers a 1-year price forecast of 1.32. Based on two analysts, no specific estimates for EPS or revenue are detailed in the provided content.", "url": "https://www.tradingview.com/symbols/GETTEX-YP1A/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-29T13:14:16", "published_display": "29 Jun 2026 13:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Immutep Ltd \u2013 ASX:IMM", "summary": "This page provides financial data for Immutep Ltd (ASX:IMM), specifically focusing on its forward Price to Earnings (P/E) ratio. It indicates that the market was closed with no trades at the time of viewing, suggesting the data presented is for informational purposes.", "url": "https://www.tradingview.com/symbols/ASX-IMM/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:39:24", "published_display": "28 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A2H8YL Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a price target and analyst ratings for Immutep Ltd Sponsored ADR (A2H8YL). One analyst offers a 1-year price forecast, with a target of 1.32. The ratings are based on two analysts over the past three months.", "url": "https://www.tradingview.com/symbols/LS-A2H8YL/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T13:10:53", "published_display": "27 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Ltd Actuals & Estimates (ASX:IMM)", "summary": "This article provides an overview of Immutep Ltd (ASX: IMM) stock performance, analyst estimates, and financial data. It covers current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports, noting that analysts have a maximum an", "url": "https://www.tradingview.com/symbols/ASX-IMM/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T13:39:03", "published_display": "26 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Ltd Actuals & Estimates (FWB:YP1B)", "summary": "This article provides financial actuals and estimates for Immutep Ltd (FWB: YP1B), an Australian biotechnology company. It details analyst forecasts, historical stock prices, recent earnings and revenue, and confirms that the company does not pay dividends. The report also highli", "url": "https://www.tradingview.com/symbols/FWB-YP1B/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:39:24", "published_display": "26 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Immutep Ltd \u2013 FWB:YP1B", "summary": "This page displays the \"Price to sales forward\" metric for Immutep Ltd (FWB:YP1B) on the Frankfurt Stock Exchange. The specific value, change, and percentage change for this metric are presented, though the actual numerical data is not visible in the provided content. The page al", "url": "https://www.tradingview.com/symbols/FWB-YP1B/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:39:03", "published_display": "26 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Immutep Ltd \u2013 FWB:YP1B", "summary": "The article discusses the enterprise value to EBITDA forward for Immutep Ltd (FWB:YP1B) on the Frankfurt Stock Exchange. It provides financial context for the company's valuation metrics.", "url": "https://www.tradingview.com/symbols/FWB-YP1B/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T05:10:34", "published_display": "26 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Shares Rise After Maxim Group Upgrade", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immutep-shares-rise-maxim-group-185629406.html", "source_name": "MT Newswires", "published_at": "2026-06-17T18:56:29+00:00", "published_display": "17 Jun 2026 18:56", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immutep-present-positive-interim-phase-120000283.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T12:00:00+00:00", "published_display": "04 Jun 2026 12:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors Should Contact SueWallSt", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxQWnVnWTNIQkxrX2UtMkpPbGFSVHh5X2JOMUpaS3FSd2hYM2ZwV2taVWZMTmJicDlLd2RsSExRQ3hGTXBYeFgwQmFTYXBXaFg4Y0VjaWhyZHNZTE4zSFNqUmM1ZVR0dHJNSFZYalNmdmU1OWFES2FpanA2YUZfeUNRcXNvRHVRZ0VqSldnay05a2hZR2J6elNMSk9PeGFYWkRtQVlQMXExLURobDhXZmt4a2FMb2hiaFlSMFNvdFVsTnZFaG5uMEMxSWdJdUQzT3B5VWd3aF81VW9iUmNlV2VCV2N1dVFPVk9kRG55dW9qUkNuZnIwcmc?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immune response to Immutep drug linked to 7.7-month survival gain", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxORk10RVRxdVlzb2pVZF9udzVzZG9nRkp6bXpLTHA2c3FlQlljMUIxTGNhYUtVeFUzRlUxXzhxWXB3SVVUTEVUNlM5aW5xZUQyenFlRkFwbERLcXp0SV9MaE1SWjJHVUJqTkhqMnF6ZkJEaFhxcE9UeDdvME9Xbnllc1lNdFVhbTI2UDZUUHhVbnhxdTNNQUhLZEdpNXhrZEliaTVXUEZ5Wm1MSmNCeGpLU3N1RWo0RmtEY2tj?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgJBVV95cUxOVzBOSDFQUlN0dmVJNXlROW1sSmZUZHBka0stVDIzeVlKa0htdjQ0aUxyaWdDclBuZkc1NDYtVkhsYmhmSHliaDdob1p6QlpaeGtjRWdaWkhlMTQzamZVRDFvZ1RPYm9KWlNaT19Cc2lVQmxTOE5VNTU3UVl6bWZ1RlFlX0ozX2RBd0IzZmU3ZFJMYVJ2cEloT2ZERU0tRXQ2VEtCMk9VRmxpeGs3aXVtMF9sZjhqQVZvalFPUHd0TXFiOHlTWXFmakQ1cmlFSTlGR25hM2F5NG9JaUd4MUFNZG5SX3ZkZjdIdTRYWE5FVDRSTlJyd2toQklndWdJWkQzczJ1S3NKLUNBRmZ1YnE5cUhn?oc=5", "source_name": "Morningstar", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Immutep (ASX:IMM) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immutep-asx-imm-good-position-220305870.html", "source_name": "Simply Wall St.", "published_at": "2026-05-10T22:03:05+00:00", "published_display": "10 May 2026 22:03", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMUTEP LIMITED (IMMP) INVESTOR ALERT Investors With Large", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAJBVV95cUxQT3c2ZGEwUWtSVUhQU1U5LUp4aEFDUnRPTklMUElYZE53dFBacjdZY0lOci1NZFpQSmtDVDI3WVQxcy1PaS1pbU5mb0xzZGE3ZUFPN3BvTW1kNUNwQTJyRElsaDJTUjQwV1VRWWNnZmlLMkU4MG14dlJHdDd2NGVBVm5aRjhaRkRNZ3pUQlB5SXRzcEtSZXRrUzk1ekNxVHhxeTJ1ejhJQUh1VHFWalA1VTNRTW12b2N0Tm53c3Bxc1ZVNWVLTzNKUjFMeDJUcVUydHEwSFZzbzNGdkl1b3ZSRmowUEJlWTlkTHhmTWNlbFhQQTdvMTRNQkx5dFhuUEVob1Z5YXUtTDlsNUJ0enNHZlVkcHVUdnpaYVpXazlVTm1teDdodUNKODBoUTdGUjhpMU5IWWZ4SmhoN0ct?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Receives Nasdaq Notice of Bid Price Deficiency", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immutep-receives-nasdaq-notice-bid-120000160.html", "source_name": "GlobeNewswire", "published_at": "2026-04-30T12:00:00+00:00", "published_display": "30 Apr 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer meeting picks Immutep poster linking immune activation to survival", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQS1gtWkViWWt5TjhhSjJPdkZ2c3pleWtMVDlyNmE4ejBoTHNFczFnYWJfX3FKaF9YdFpxejhCYzRYZGI1eDFjVjZWbmVfWDk5NzhMYk83QUF2X0trNVJpTGprZ055RER5OGFIc1hRU3ZUQ1dpR1BkY20zaUpZREhSOXJCa0RsXzZYMHYtVW51bV9XV0ptc1dFYi16c0VyVk1XYV9aUlcxclppaV9IMV9HUVhraVBpQ2ttNWhmejB6U0M?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep shares more than double after FDA grants orphan drug designation for sarcoma candidate", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOaW80OXY0XzIzVmwxd2VabzJpNEtmX01mdmplR1N2Z0JnRXJaY0VZZHhBbjc4TzdxZ0ZGdl9hUjdfTndMSDRYQU4waV9YRjY1QV9qMnlqWURhNmQ2WTMyYTV4UlN4bXdkdzJHa2l6YlBQYTF3Y3NVTTVBNXZkMEV4WnByRHh6QXRQdXdrTWdCdnhnaXpSMEVKSWREWURyQTZ3VjZ0WGpmMEs1aC1pOE1rTVotY2dEUllkM2JMUTZPSmNWMXQyVUE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Limited (IMMP) Stock Analysis: Uncovering A Potential 171.74% Upside In Biotech", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPYWNNWTRlTGRuQkFJdXBXUkFESldSQlZqaHBRTVlfOWNkb2dkUHZhampLcTlHMnZlZFhHUmduNXlqRU5la1hSZnpoM1lURENiSEpYeVBSU2RfY2duWldJbzI5RklTcW9kc212QUkyZ24zc0xKWWZSTDQ0cEdQN0ZVX1MyelJjZ3U1QWVpV3NKS0pwQk05NUE5X0pSUEl1ejBMdGVBcm1PSjEtQnB1aXc5d1p4N1cwaDNZZ2VQZ3Q1ZDZ0bHBBV2dUTERCdlZTaEk?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Limited (IMMP) Stock Analysis: Navigating a Potential 140% Upside in the Biotech Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxPT1VqNlRoZVA2bl9rb09vYlZ2TGlhVFRKdHRNY1dpOHV5Y2hGWWphY2hsUnNON2plejhGWTJGeU1yaGdmTmdGWFhyTkp5WVgyTnpFaXJFZVdYVXh4d2wtQWxqLWd0LVVBVGdMNmF5OWo5NkU4LVVOamVKSXVtaFRCM3QycVJISGxHSjNZZXcwNTJfWm1XYzRtYTlrNmotakQxRUVpak41S3huV0RKV19UTE5Zb2VqVTJqNHNxdDQxMmxXM29hemRhRTJ6WVZ1aHNpWTBOa0dNMkhCQQ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep stock plunges 80% after lung cancer trial halted", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPaFdudFFUbFJveXZEaVlGcXY5T1JNdjlNbFJnUzBaN2FfeElsRlJ5QnljbWFEMHFvNzlLZUtKY0d4c2ZLd1hjQnlWMzR3TmREQkhqMWpQQWdrSTdzSlAwdGxPWUVoMWJ6Vnd2NnlubVNJa2c1T1hmUkF6aXNLcHljbXpsSjFPT1lVWEcxaktoM0t5YzNrUFFGTUJkc2dEOTEyQUd5M21lTEFZTmhRN3l2NU1IU1Y0OHgy?oc=5", "source_name": "Investing.com", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens downgrades Immutep stock rating on lead program halt", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPdXZoZlRvUmpkcFRkdHFlcVc4em4wQ0ZZeHI5Z3FibzRVLVVlYkdXNE1JVjZlMTc3RkMwS2M5bUJxdWxibXB1WjFNY0tUWG9tMExueS1xLXhERXo5cV9FeVB0bjMyQUJIRnAwaE5SWmM3Z2IzX0ROZ3FBazBRTnpMTWUzUkJxdGVqZjhvTHZqT3lxZk9MMURsekdGRUpLUXZiaEZFUzJsR0hnU1ZLS3dDWUpDQmNYempkRDZVMkNn?oc=5", "source_name": "Investing.com", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Stock Sinks To 52-Week Low - Here's Why - Immutep (NASDAQ:IMMP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPLTE3SHhlVU1vVnBJeHBNczZBZkhoVEwtdHpRNzRrMDh2QlpjUnROOExwZ25jeUVvLVdETHl5RjV6TWZrMXBjMlMzaXlmTGZCSTQ2WVp4OTlna0pTeDctMnBKdmZ1bnJoaWdfREluUXlTSVh1eGRwUm5yT0JkM09lUVVxUzZXUDZ1MkJwalhVVGU5SFhUNkhMLVRhUHR3QXNGNXNMRkNqaDRtTUpIME14QXRHeWlsRklTV2VlMFJxMFpjWlBSX0tXYmFFRjA0Zw?oc=5", "source_name": "Benzinga", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Limited (IMMP) Stock Analysis: Exploring a Promising 247.99% Upside in Biotechnology", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxOS1ZVUmkyRTJXZk1zZ0ppMzB5RDlZUlVDRnJoek5RMmlsR3hLbXlOeWxsMEVfb2htTkNaUE9vN1VtLW9PYlM1Sm80ZDhtRjhTd1g1YUJMNzU2Snh5SlBVZEEzdHF5YUZvaU5jX0oxT1MzVVVUdk5oTUJEeWRXWkkyVGZfd0hVb0JmVkpmRFlzamx0QkJxTzBta08wcHdQNjRneTFXNFBhMkNiR29VT3VqTC1kTlBhNi1uTXhUeEdubDE3X3dfbGNPVmFvcWVna2wtVkhFeWJn?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Limited (IMMP) Stock Analysis: A 240% Potential Upside In Immunotherapy Breakthrough", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPSGlQV0xtZ3owcTNLUFlMTWEyeFdrWjVkWU9JUWt2bGpJNUdXckJTeFZhZjdmMGF2OUFNOUF3TUF3YUp2ZUJ1Z19fNXU3WEVvMGNNTUlrOE91X2JUX0JWNmtXcklPS3pNSUNJdUhkSExQWklvVnBxMVh1R2JEMGFQSGdlWG9hX05LbFVxMHZmUFR6R3FfOFh3ZDRxWkZqMTNNOXNocmxQQ1dGODBDSG5OR0tsZVhYZHdZYm9qMXFOWFJGRFhMUV9ET3RSU056SHFBUG92cG9n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immutep Limited (IMMP) Stock Analysis: Exploring a Potential 208% Upside in Biotechnology", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxNVnlKTkt5RjUtejFuYV9hblJONmNnd3NzN245alU1bjRoLU04Nl9nWk9NM09TUENVTF9IQVRrUzNmdEF3aG1uWUVDV3F6eXluNERQQ1JvdXlzVHdfOV84M29TdE1jLXFVUHJQYVFIOUxaa2RDaW5zRzVXRElhNVdsejdsdnJDVzRlNWY1ZTk5cl9icFRRQnZmMFpsVEI2d2E3R0thOEQwT1lNdzU5aVk4TEdfWlhFQ2dNVHd4d1BSOEpVTnRvOGtya0dZN3E4c1NQdUE?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2025-12-25T08:00:00+00:00", "published_display": "25 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 56, "sentiment_summary": {"positive": 16, "negative": 7, "neutral": 33, "score": 52, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 16.5, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 7.56, "count": 16}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.65, "count": 6}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}], "positive_events": 16, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 0.41, "latest_week": "2026-07-17", "one_week_move": -2.2, "four_week_move": 9.5, "twelve_week_move": -28.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.291016, "market_dynamics_buy_signal": false, "relative_strength": -76.893899, "fair_value_gap": -78.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 49.6549, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.2% over one week, +9.5% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 10}, {"label": "Market source", "count": 7}, {"label": "GlobeNewswire", "count": 6}, {"label": "Stock Titan", "count": 5}, {"label": "DirectorsTalk Interviews", "count": 5}, {"label": "Moomoo", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "PR Newswire", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 47}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 16}, {"label": "Regulatory and legal", "count": 6}, {"label": "Analyst action", "count": 4}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "47", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.2% over one week, +9.5% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Immutep(IMMP) Stock Options Chain | Quotes & News"}], "updated_at": "2026-07-23T10:29:46.409461+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}